Iowa Patent of the Month – May 2024

NanoMedTrix, LLC has made significant strides in the field of nanomedicine with their innovative composition for bladder tumor monitoring and therapeutic delivery. This newly patented invention leverages mesoporous silica nanoparticles (MSNs), functionalized with detectable agents such as lanthanides, fluorophores, or ultrasound-sensitive materials. These MSNs are uniquely capped with gelatin or synthetic phospholipid bilayers and linked with a bladder cancer-specific peptide, Cyc6, ensuring precise targeting and monitoring of bladder cancer cells.

The design of these MSNs is particularly noteworthy. By incorporating materials like trifluoropropyl groups, gold, bismuth, and iron oxide, the nanoparticles achieve superior imaging capabilities across various modalities, including MRI, CT, and ultrasound. This multi-functionality is crucial for comprehensive cancer diagnostics and monitoring.

In addition to their diagnostic prowess, these MSNs are adept at delivering bioactive agents directly to bladder cancer cells. The nanoparticles can be loaded with potent therapeutic agents such as cannabidiol, epirubicin, mitomycin-c, gemcitabine, and docetaxel. This targeted delivery system ensures that the therapeutic agents are released precisely where needed, maximizing efficacy while minimizing side effects.

The MSNs’ innovative capping mechanism with gelatin or synthetic phospholipid bilayers, cross-linked with glutaraldehyde, enhances their stability and controlled release properties. The gelatin used is specially designed to melt at body temperature, ensuring the release of therapeutic agents at the right time and place.

This breakthrough not only holds promise for improving bladder cancer treatment outcomes but also for reducing the recurrence rates by ensuring sustained and precise delivery of therapeutic agents. NanoMedTrix’s pioneering work in nanoparticle technology thus represents a significant advancement in the fight against bladder cancer, offering hope for more effective and less invasive treatment options.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at or contact your usual Swanson Reed representative.

Recent Posts